These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 7719287)

  • 1. Binding to fibronectin (FN)--a prerequisite step? Investigations on the role of FN in intravesical BCG immunotherapy.
    Böhle A; van der Sloot E; Richter E; Gerdes J; Wood WG; Jocham D
    Investig Urol (Berl); 1994; 5():100-4. PubMed ID: 7719287
    [No Abstract]   [Full Text] [Related]  

  • 2. [Severe self-limiting hypersensitivity reaction after immunotherapy with intravesical BCG].
    Estelles Piera FJ; Campayo A; Valls Ferrer JM; Lacruz J; Blanes Julia FM; López Aldeguer J; Bonora Tamarit V
    An Med Interna; 1994 Oct; 11(10):503-5. PubMed ID: 7865660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravesical bacille Calmette-Guérin therapy for muscle invasive bladder cancer.
    Rosenbaum RS; Park MC; Fleischmann J
    Urology; 1996 Feb; 47(2):208-11. PubMed ID: 8607236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of fibronectin in intravesical BCG therapy for superficial bladder cancer.
    Ratliff TL; Kavoussi LR; Catalona WJ
    J Urol; 1988 Feb; 139(2):410-4. PubMed ID: 3276931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Reiter syndrome after intravesical Bacillus Calmette-Guerin (BCG) immunotherapy: a case report].
    Shiba M; Fujii T; Takatera H
    Hinyokika Kiyo; 2003 Oct; 49(10):599-601. PubMed ID: 14655604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bladder and penile lesions with inguinal adenopathy after intravesical Bacillus Calmette-Guerin (BCG) treatment.
    Yates J; Stein B
    Urology; 2007 Dec; 70(6):1223.e15-7. PubMed ID: 18158061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of action of intravesical BCG for bladder cancer.
    Ratliff TL
    Prog Clin Biol Res; 1989; 310():107-22. PubMed ID: 2672010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravesical therapy for superficial bladder cancer.
    Malkowicz SB
    Semin Urol Oncol; 2000 Nov; 18(4):280-8. PubMed ID: 11101091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Intravesical adjuvant chemotherapy for superficial bladder cancer -- results of a survey in Saxony].
    Steinbach F; Schuster F
    Aktuelle Urol; 2005 Aug; 36(4):337-41. PubMed ID: 16110407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Re: Salvatore Siracusano, Francesca Vita, Rita Abbate, Stefano Ciciliato, Violetta Borelli, Massimiliano Bernabei and Giuliano Zabucchi. The role of granulocytes following intravesical BCG prophylaxis. Eur Urol 2007;51:1589-99.
    Brandau S; Suttmann H
    Eur Urol; 2007 Oct; 52(4):1266-7; author reply 1268-9. PubMed ID: 17560711
    [No Abstract]   [Full Text] [Related]  

  • 11. Management of superficial transitional cell carcinoma of the bladder.
    Fleischmann J; Goldberg G
    Semin Urol; 1993 Nov; 11(4):193-204. PubMed ID: 8290825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New-onset psoriasis and psoriatic arthritis in a patient treated with Bacillus Calmette-Guérin (BCG) immunotherapy.
    Dudelzak J; Curtis AR; Sheehan DJ; Lesher JL
    J Drugs Dermatol; 2008 Jul; 7(7):684. PubMed ID: 18664162
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of local pentosan polysulphate pretreatment on the immune response to intravesical BCG.
    de Boer EC; Schamhart DH; Vos PC; Vleeming R; Kurth KH
    Investig Urol (Berl); 1994; 5():95-9. PubMed ID: 7536525
    [No Abstract]   [Full Text] [Related]  

  • 14. Tubercular prostatic abscess as a complication of intravesical bacillus Calmette-Guérin immunotherapy.
    Aust TR; Massey JA
    Int J Urol; 2005 Oct; 12(10):920-1. PubMed ID: 16323989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients.
    Peyromaure M; Guerin F; Amsellem-Ouazana D; Saighi D; Debre B; Zerbib M
    J Urol; 2003 Jun; 169(6):2110-2. PubMed ID: 12771729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravesical bacillus Calmette-Guérin therapy for T1 superficial bladder cancer.
    Demkow T; Alter A; Wiechno P
    Urol Int; 2008; 80(1):74-9. PubMed ID: 18204238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravesical bacille Calmette-Guérin induces the antiangiogenic chemokine interferon-inducible protein 10.
    Poppas DP; Pavlovich CP; Folkman J; Voest EE; Chen X; Luster AD; O'Donnell MA
    Urology; 1998 Aug; 52(2):268-75; discussion 275-6. PubMed ID: 9697793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific binding of bacillus Calmette-Guérin to urothelial tumor cells in vitro.
    Schneider B; Thanhäuser A; Jocham D; Loppnow H; Vollmer E; Galle J; Flad HD; Ulmer AJ; Böhle A
    World J Urol; 1994; 12(6):337-44. PubMed ID: 7881473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T2a transitional cell carcinoma of the bladder: long-term experience with intravesical immunoprophylaxis with bacillus Calmette-Guerin.
    Volkmer BG; Gschwend JE; Maier SH; Seidl-Schlick EM; Bach D; Romics I
    J Urol; 2003 Mar; 169(3):931-4; discussion 934-5. PubMed ID: 12576815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A rare case of BCG vaccinal sepsis in a patient with bladder cancer].
    Gorobets ES; Sviridova SP; Gromova EG; Figurin KM
    Anesteziol Reanimatol; 1997; (6):54-5. PubMed ID: 9511249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.